News

Weighing individual cancer cells could help doctors predict how multiple myeloma patients will respond to treatments, a Massachusetts Institute of Technology study reports. The findings could…

The U.S. Food and Drug Administration (FDA) has granted Celgene and Bluebird Bio’s bb2121 — the first CAR T-cell therapy for multiple myeloma —…

The U.S. Food and Drug Administration (FDA) agreed to allow two clinical trials of Opdivo (nivolumab)-based combinations for myeloma to resume, after being put on partial…

The U.S. Food and Drug Administration (FDA) has accepted Ascentage Pharma‘s Investigational New Drug (IND) application for APG-1387, allowing Ascentage to test the…

A Japanese study has found that an active structure of the protein integrin β7 is specific to multiple myeloma cells, suggesting that it could be…

The first patient-led crowdsourcing and crowdfunding initiative for multiple myeloma (MM) research has exceeded its goal of raising $500,000 to advance new…

Janssen Pharmaceuticals has requested the U.S. Food and Drug Administration (FDA) add a new indication for Darzalex (daratumumab) in combination with other therapies…

Adaptive Biotechnologies has partnered with Amgen to use Adaptive’s NGS-based clonoSEQ Assay in a Phase 3 clinical trial led by Amgen to…

Janssen Pharmaceuticals recently submitted a Type 2 variation application to the European Medicines Agency (EMA) seeking to broaden the existing marketing authorization for…

Poseida Therapeutics is developing CAR T-cell therapies that can get rid of cancer-generating bone marrow cells before a blood cancer patient receives a stem…